This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Take a Look at the Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
5 Best Leveraged ETFs of Last Week
by Sanghamitra Saha
We highlight a few leveraged ETF areas that won last week.
Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak
by Sweta Jaiswal, FRM
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
4 Best-Performing Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Last week witnessed a tug-of-war between bulls and bears.
Biotech ETFs in Focus on String of Q1 Earnings Beats
by Sweta Jaiswal, FRM
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
Will Biotech ETFs Continue to Rally in Q1 Earnings?
by Sweta Jaiswal, FRM
Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .
3 ETFs to Watch on Biotech Earnings
by Zacks Equity Research
Major Biotech companies report mixed Q4 results.
3 ETFs to Watch on Biotech Earnings
by Zacks Equity Research
Major Biotech companies report mixed Q3 results.
Should You Keep Your Portfolio Healthy with Biotech ETFs?
by Sanghamitra Saha
Biotech ETFs are riding high on research and developments and FDA approvals.
3 ETFs to Watch Out for on Biotech Earnings
by Zacks Equity Research
Major players in the biotech space reported their second quarter 2017 results.
5 Reasons Why Biotech ETFs are Soaring
by Sanghamitra Saha
Reasons that propelled the biotech space and the related ETFs higher.
4 Stocks & ETFs to Buy on Clovis' Positive Drug Data
by Sanghamitra Saha
Clovis Oncology clinical trial data has given a boost to the biotech sector and put these stocks and ETFs in focus.